Palvella Therapeutics Prices Upsized Public Offering

Got story updates? Submit your updates here. ›

Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel therapies for rare skin diseases, announced the pricing of its upsized public offering of 1,600,000 shares of common stock at $125.00 per share. The company expects to raise gross proceeds of $200 million from the offering, which it plans to use to support the development of its QTORIN rapamycin and QTORIN pitavastatin programs.

Why it matters

Palvella's public offering will provide critical funding to advance its pipeline of investigational treatments for serious, rare skin diseases that currently lack FDA-approved therapies. The company's lead candidates, QTORIN rapamycin and QTORIN pitavastatin, target conditions like microcystic lymphatic malformations, cutaneous venous malformations, and disseminated superficial actinic porokeratosis.

The details

The public offering was upsized from the initial plan, with Palvella selling 1,600,000 shares of common stock at $125.00 per share. The company also granted the underwriters a 30-day option to purchase up to an additional 240,000 shares. The offering is expected to close on or about February 27, 2026, subject to customary closing conditions.

• The public offering was priced on February 25, 2026.
• The offering is expected to close on or about February 27, 2026.

What’s next

The offering is expected to close on or about February 27, 2026, subject to the satisfaction of customary closing conditions.